Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on developing novel antibody therapeutics in immunology and oncology, has announced a strategic collaboration with Evinova China, a global health-tech company accelerating digital transformation in the life sciences sector. The partnership, unveiled during the 8th China International Import Expo (CIIE) in Shanghai, aims to harness artificial intelligence (AI) and digital technologies to enhance the efficiency of innovative biologics development. The two companies will jointly build an open ecosystem for AI-driven drug research and development, combining Harbour BioMed’s deep therapeutic expertise with Evinova’s advanced AI platforms and digital strategy solutions. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, expressed enthusiasm for the collaboration, stating that the integration of AI into biotherapeutic development will improve clinical study efficiency and accelerate the delivery of innovative therapies to patients worldwide. Harbour BioMed’s proprietary Harbour Mice® platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. This foundation supports the company’s next-generation technologies, including HBICE® (HCAb-based immune cell engagers) for cancer treatment and HBICATM (HCAb-based bispecific immune cell antagonists) for immunological and inflammatory diseases. By integrating these platforms with a single B-cell cloning system, Harbour BioMed has created a highly efficient and distinctive antibody discovery engine. Nate Zhang, General Manager of Evinova China, emphasized the importance of collaboration in advancing global health outcomes. He noted that Evinova leverages digital transformation insights from leading pharmaceutical companies to design AI-powered clinical development tools and consulting services. Partnering with innovative, China-rooted yet globally ambitious companies like Harbour BioMed, Evinova aims to help bring breakthrough therapies from the lab to the world. The collaboration is a key step in Evinova’s mission to drive better health outcomes through science-based, human-centered digital solutions. Evinova operates as a separate health-tech business within the AstraZeneca Group and is dedicated to propelling the life sciences industry forward through evidence-led, experience-driven digital innovation. The company’s focus is on creating tools that improve the speed, accuracy, and efficiency of drug development, from early research to clinical delivery. This partnership represents a significant move in the convergence of biopharmaceutical innovation and AI, particularly in the context of China’s growing role in global biotech. By combining Harbour BioMed’s cutting-edge antibody technologies with Evinova’s AI and digital strategy capabilities, the collaboration aims to reduce development timelines, lower costs, and increase the success rate of novel therapeutics. The open ecosystem they are building could serve as a model for future industry-wide collaboration, fostering innovation and accelerating the translation of scientific discoveries into real-world treatments. The announcement underscores a broader trend: the integration of AI into every stage of drug development. As the pharmaceutical industry faces increasing pressure to deliver new treatments faster and more efficiently, strategic alliances like this one are becoming essential. With Harbour BioMed’s strong pipeline and Evinova’s digital expertise, the partnership is poised to set a new standard in AI-enabled biologics R&D, benefiting patients, researchers, and the global health community.